Targeting Glutamate Synapses in Schizophrenia

Overview

Journal Trends Mol Med

Specialties General Medicine
Molecular Biology

Date 2011 Sep 30

PMID 21955406

Citations 49

Authors

Julie R Field

Adam G Walker

P Jeffrey Conn

Affiliations

Soon will be listed here.

Abstract

Although early clinical observations implicated dopamine dysfunction in the neuropathology of schizophrenia, accumulating evidence suggests that multiple neurotransmitter pathways are dysregulated. The psychotomimetic actions of NMDA receptor antagonists point to an imbalance of glutamatergic signaling. Encouragingly, numerous preclinical and clinical studies have elucidated several potential targets for increasing NMDA receptor function and equilibrating glutamatergic tone, including the metabotropic glutamate receptors 2, 3 and 5, the muscarinic acetylcholine receptors M(1) and M(4), and the glycine transporter GlyT1. Highly specific allosteric and orthosteric ligands have been developed that modify the activity of these novel target proteins, and in this review we summarize both the glutamatergic mechanisms and the novel compounds that are increasing the promise for a multifaceted pharmacological approach to treat schizophrenia.

Citing Articles

Mechanisms of Action Underlying Conductance-Modifying Positive Allosteric Modulators of the NMDA Receptor.

Ullman E, Perszyk R, Paladugu S, Fritzemeier R, Akins N, Jacobs L Mol Pharmacol. 2024; 106(6):334-353.

PMID: 39443157 PMC: 11585258. DOI: 10.1124/molpharm.124.001019.

The Nitric Oxide (NO) Donor Molsidomine Attenuates Memory Impairments Induced by the D1/D2 Dopaminergic Receptor Agonist Apomorphine in the Rat.

Vartzoka F, Ozenoglu E, Pitsikas N Molecules. 2023; 28(19).

PMID: 37836704 PMC: 10574075. DOI: 10.3390/molecules28196861.

Positive allosteric adenosine A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice.

Lin Y, Roy K, Ioka S, Otani R, Amezawa M, Ishikawa Y Front Pharmacol. 2023; 14:1138666.

PMID: 37153764 PMC: 10155833. DOI: 10.3389/fphar.2023.1138666.

The Nitric Oxide (NO) Donor Molsidomine Counteract Social Withdrawal and Cognition Deficits Induced by Blockade of the NMDA Receptor in the Rat.

Katsanou L, Fragkiadaki E, Kampouris S, Konstanta A, Vontzou A, Pitsikas N Int J Mol Sci. 2023; 24(7).

PMID: 37047839 PMC: 10095209. DOI: 10.3390/ijms24076866.

Cognitive Rehabilitation in Schizophrenia-Associated Cognitive Impairment: A Review.

Zoupa E, Bogiatzidou O, Siokas V, Liampas I, Tzeferakos G, Mavreas V Neurol Int. 2023; 15(1):12-23.

PMID: 36648966 PMC: 9844333. DOI: 10.3390/neurolint15010002.

References

Coyle J . Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006; 26(4-6):365-84. PMC: 11881825. DOI: 10.1007/s10571-006-9062-8. View

Marino M, ROUSE S, Levey A, Potter L, Conn P . Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A. 1998; 95(19):11465-70. PMC: 21666. DOI: 10.1073/pnas.95.19.11465. View

Lebois E, Bridges T, Lewis L, Dawson E, Kane A, Xiang Z . Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci. 2011; 1(2):104-121. PMC: 3180826. DOI: 10.1021/cn900003h. View

Johnson M, Barda D, Britton T, Emkey R, Hornback W, Jagdmann G . Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl). 2005; 179(1):271-83. DOI: 10.1007/s00213-004-2099-9. View

Pehrson A, Moghaddam B . Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion. Psychopharmacology (Berl). 2010; 211(4):443-55. PMC: 2954604. DOI: 10.1007/s00213-010-1914-8. View

Homayoun H, Jackson M, Moghaddam B . Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol. 2004; 93(4):1989-2001. DOI: 10.1152/jn.00875.2004. View

Kinon B, Potts A, Watson S . Placebo response in clinical trials with schizophrenia patients. Curr Opin Psychiatry. 2011; 24(2):107-13. DOI: 10.1097/YCO.0b013e32834381b0. View

Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B . Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry. 2007; 62(7):739-46. PMC: 2910402. DOI: 10.1016/j.biopsych.2006.12.003. View

Black M, Varty G, Arad M, Barak S, De Levie A, Boulay D . Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl). 2008; 202(1-3):385-96. DOI: 10.1007/s00213-008-1289-2. View

10.

Rodriguez A, Williams R, Zhou Y, Lindsley S, Le U, Grier M . Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg Med Chem Lett. 2009; 19(12):3209-13. PMC: 3177605. DOI: 10.1016/j.bmcl.2009.04.110. View

11.

Shirey J, Brady A, Jones P, Davis A, Bridges T, Kennedy J . A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009; 29(45):14271-86. PMC: 2811323. DOI: 10.1523/JNEUROSCI.3930-09.2009. View

12.

Schlumberger C, Schafer D, Barberi C, More L, Nagel J, Pietraszek M . Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol. 2009; 20(1):56-66. DOI: 10.1097/FBP.0b013e3283242f57. View

13.

Bradley S, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D . AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology. 2009; 58(2):365-73. DOI: 10.1016/j.neuropharm.2009.10.003. View

14.

OBrien J, Lemaire W, Chen T, Chang R, Jacobson M, Ha S . A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol. 2003; 64(3):731-40. DOI: 10.1124/mol.64.3.731. View

15.

Lindsley C, Shipe W, Wolkenberg S, Theberge C, Williams Jr D, Sur C . Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem. 2006; 6(8):771-85. DOI: 10.2174/156802606777057599. View

16.

Kopec K, Flood D, Gasior M, McKenna B, Zuvich E, Schreiber J . Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem Pharmacol. 2010; 80(9):1407-17. DOI: 10.1016/j.bcp.2010.07.004. View

17.

Gregory K, Sexton P, Christopoulos A . Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol. 2009; 5(3):157-67. PMC: 2656816. DOI: 10.2174/157015907781695946. View

18.

Kinney G, Sur C, Burno M, Mallorga P, Williams J, Figueroa D . The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci. 2003; 23(20):7586-91. PMC: 6740762. View

19.

Cartmell J, Monn J, Schoepp D . The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther. 1999; 291(1):161-70. View

20.

Marlo J, Niswender C, Days E, Bridges T, Xiang Y, Rodriguez A . Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol. 2008; 75(3):577-88. PMC: 2684909. DOI: 10.1124/mol.108.052886. View